Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 2%

Aligos Therapeutics, Inc. (NASDAQ:ALGSGet Free Report)’s stock price rose 2% on Monday . The company traded as high as $0.43 and last traded at $0.41. Approximately 587,431 shares traded hands during trading, an increase of 60% from the average daily volume of 366,918 shares. The stock had previously closed at $0.40.

Aligos Therapeutics Trading Up 2.0 %

The firm has a market cap of $32.18 million, a price-to-earnings ratio of -0.32 and a beta of 2.19. The business’s 50-day simple moving average is $0.57 and its two-hundred day simple moving average is $0.73.

Aligos Therapeutics (NASDAQ:ALGSGet Free Report) last released its earnings results on Tuesday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The firm had revenue of $0.99 million for the quarter. Aligos Therapeutics had a negative net margin of 783.72% and a negative return on equity of 144.16%. On average, analysts forecast that Aligos Therapeutics, Inc. will post -0.73 earnings per share for the current fiscal year.

Institutional Trading of Aligos Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $4,538,000. Altitude Crest Partners Inc. acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $1,889,000. Opaleye Management Inc. grew its position in shares of Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after buying an additional 333,000 shares during the period. Vanguard Group Inc. grew its position in shares of Aligos Therapeutics by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,010,617 shares of the company’s stock worth $755,000 after buying an additional 15,905 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of Aligos Therapeutics by 17.6% during the 1st quarter. Acadian Asset Management LLC now owns 657,995 shares of the company’s stock worth $644,000 after buying an additional 98,628 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

About Aligos Therapeutics

(Get Free Report)

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Recommended Stories

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.